Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2008-04-15
2010-06-08
Juedes, Amy E (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S278100
Reexamination Certificate
active
07731973
ABSTRACT:
The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.
REFERENCES:
patent: 5194425 (1993-03-01), Sharma et al.
patent: 5223426 (1993-06-01), Skibbens et al.
patent: 5569585 (1996-10-01), Goodwin et al.
patent: 5612035 (1997-03-01), Howell et al.
patent: 5614192 (1997-03-01), Vandenbark
patent: 5776459 (1998-07-01), Vandenbark
patent: 5837246 (1998-11-01), Howell et al.
patent: 5856446 (1999-01-01), Weiner et al.
patent: 5858968 (1999-01-01), Weiner et al.
patent: 5869093 (1999-02-01), Weiner et al.
patent: 5939281 (1999-08-01), Lehmann et al.
patent: 5939400 (1999-08-01), Steinman et al.
patent: 6019971 (2000-02-01), Weiner et al.
patent: 6039947 (2000-03-01), Weiner et al.
patent: 6045796 (2000-04-01), Sriram et al.
patent: 6090387 (2000-07-01), Howell et al.
patent: 6113903 (2000-09-01), Albertini et al.
patent: 6159470 (2000-12-01), Howell et al.
patent: 6197926 (2001-03-01), Gaur
patent: 6207645 (2001-03-01), Howell et al.
patent: 6218132 (2001-04-01), Spack et al.
patent: 6221352 (2001-04-01), Howell et al.
patent: 6936599 (2005-08-01), Voskuhl
patent: 6958327 (2005-10-01), Hillisch et al.
patent: 2002/0183299 (2002-12-01), Voskuhl
patent: 0 159 739 (1985-10-01), None
patent: 10175854 (1998-06-01), None
patent: 957359 (1999-11-01), None
patent: WO 94/25063 (1994-11-01), None
patent: WO 99/58977 (1999-11-01), None
patent: WO 01/32680 (2001-05-01), None
van den Brink et al., 1993, Ann. Rheum. Dis. vol. 52: 862-865.
Acha-Orbea et al., “Limited Heterogeneity of T Cell Receptors from Lymphocytes Mediating Autoimmune Encephalomyelitis Allows Specific Immune Intervention,”Cell, 54(2):263-273 (1988).
Arden et al.,Immunogenetics42:355-500 (1995).
Bebo et al.,J. Immunol. 162:35 (1998).
Bebo et al.,J. Neurosci. Res. 52:420-429 (1998).
Bourdette et al.,Cell Immunol. 112:351 (1988).
Brosterhaus et al., “Enrichment and detection of live antigen-specific CD4+ T cells based on cytokine secretion,”Eur. J. Immunol. 29:4053-4059 (1999).
Bourdette et al., “A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis,” Multiple Sclerosis, 11:1-10, (Jul. 5, 2005).
Choi et al.,Proc. Natl. Acad. Sci. USA86:8941-8945 (1989).
Carlsten et al., Infamm Res. vol. 45:26-30, (1996).
Chou et al., “Immunity to TCR peptides in multiple sclerosis,”J. Immunol152:2520-2529 (1994).
Chou et al., “MCH-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR Vβ CDR2 peptides: comparison with myelin basic protein-specific T cells,”J. Neuroscience Res. 45:838-851 (1996).
Cochlovius et al.,J. Immunol. 165:4731-4741 (2000).
Concannon et al.,Proc. Natl. Acad. Sci. USA83:6598-6602 (1986).
Correale et al.,J. Immunol. 161:3365-3374 (1998).
Dalton et al.,Science259:1739-1742 (1993).
English Translation of Japanese Patent Application No. JP101175854, dated Jun. 30, 1998, found at http://www4.jpdl.ncipi.go.jp/cgi-bin/tran, printed Sep. 14, 2006.
Evavold et al.,Immunology Today14:602-609 (1993).
Fairchild,Euro. J. Immunogenet. 24:155-167 (1997).
Genevee et al.,Eur. J. Immunol. 22:1261-1269 (1992).
Gilmore et al.,J. Immunol. 158:446-451 (1997).
Goverman et al.,Cell72:551-560 (1993).
Hashim et al.,J. Immunol. 144:4621-4627 (1990).
Jansson et al.,Journal of Neuroimmunology53:203-207 (1994).
International Search Report from the prior PCT Application No. PCT/US01/40710, 7 pages (Sep. 9, 2002).
Kimura et al.,Eur. J. Immunol. 17:375-383 (1987).
Kumar et al.,J. Exp. Med. 178:909-916 (1993).
Martin et al.,Nat. Immunol. 2:785-788 (2001).
Offner et al.,J. Immunol. 161:2178-2186 (1998).
Offner et al.,Journal of Clinical Investigation105(10):1465-1472 (2000).
Olsson et al., “Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ,”J. Clin. Invest. 86:981-985 (1990).
Robinson et al.,J. Immunol. 146:4392-4397 (1991).
Roselli et al.,Endocrine64:139 (1996).
Rovaris et al.,J. Neurol. Sci. 186 Suppl. 1:S3-9 (2001).
Savoie et al.,Pac. Symp. Biocomput. 1999:182-189 (1999).
Sicotte et al.,Ann. Neurol. 52:421-428 (2002).
Soldan et al., “Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol,”J. Immunology171:6267-6274 (2003).
Steinman et al.,Trends in Immunology26:565-571 (2005).
Thornton and Shevach, “CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production,”J. Experimental Medicine188(2):287-296 (1998).
Van Epps, “Thomas Rivers and the EAE Model,”JEM202(1):4 (2005).
Vandenbark et al., “Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trail,”Nature Med. 2:1109-1115 (1996).
Vandenbark, “TCR Peptide Vaccination in Multiple Sclerosis: Boosting a Deficient Natural Regulatory Network that may Involve TCR-Specific CD4+CD25+ Treg Cells,”Current Drug Targets4:217-229 (2005).
Vaniene et al.,J Neurosci. Res. 45:475-486 (1996).
Venken et al., “Secondary Progressive in Contrast to Relapsing-Remitting Multiple Sclerosis Patients Show a Normal CD4+CD25+ Regulatory T-Cell Function and FOXP3 Expression,”J. Neuroscience Research83:1432-1446 (2006).
WPI Database, Derwent Publkications Ltd., London, GB, AN 1998-422294, XP0021 89653 and JP 10 175854A (Doctors Cosmetic YG) Abstract (1998).
Zipp et al.,Brain121:1395-1407 (1998).
Alonso et al., “Recent Use of Oral Contraceptives and the Risk of Multiple Sclerosis,”Arch Neurol, 62:1362-1365, (2005).
“Progress in Autoimmune Disease Research,”National Institute of Allergy and Infectious Diseases, pp. 1-126, (Mar. 2005).
Zheng et al., “Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production,”Autoimmunity, 41(5):363-371, (Jul. 2008).
Juedes Amy E
Klarquist & Sparkman, LLP
Oregon Health and Science University
The United States of America as represented by the Department of
LandOfFree
Method of treating immune pathologies with low dose estrogen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating immune pathologies with low dose estrogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating immune pathologies with low dose estrogen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4229804